Truncated ALK Transcript in Solid Tumours: Hyped Biomarker or Biological Enigma?

A mysterious truncated version of a famous cancer gene has been stirring debate among oncologists for nearly a decade, and a new narrative review published in Molecular Biology Reports by medical oncologists Miguel Borregón, María-Asunción Algarra and Javier-David Benítez-Fuentes of hospitals in Alicante, Spain, now offers the most sobering assessment yet. The transcript, known as ALK ATI for alternative transcription initiation, is a shortened RNA message produced from a hidden promoter buried inside intron 19 of the anaplastic lymphoma kinase gene. Unlike the full-length receptor, which spans the cell membrane and senses external growth signals, the ALK ATI protein keeps the intracellular kinase domain, the molecular engine that fires growth signals, while discarding the extracellular and transmembrane regions entirely. The result is a cytoplasmic, and in some contexts nuclear, kinase fragment whose biological and clinical significance has remained stubbornly unsettled since its discovery.

The story of ALK itself is one of the great sagas of precision oncology. First identified in 1994 as part of an NPM-ALK fusion in non-Hodgkin lymphoma, the gene later achieved fame when the EML4-ALK fusion was discovered in non-small-cell lung cancer in 2007, opening the door to a series of remarkably effective ALK inhibitors such as crizotinib and its successors. ALK can be activated in cancer through several distinct mechanisms: gene fusions that create constitutively active chimeric kinases, activating point mutations, copy-number gains and amplifications, and abnormal transcriptional regulation. Each of these mechanisms is now routinely tested for in clinical laboratories, and each carries a different therapeutic implication. The question raised by ALK ATI is whether this alternative transcript represents a fifth, previously underappreciated route to ALK-driven malignancy, or whether it is a biological curiosity that has been overinterpreted by clinicians hungry for new actionable targets.

The original discovery, reported by Wiesner and colleagues in Nature in 2015, was striking. The researchers found that a subset of melanomas expressed ALK protein without any detectable gene fusion, and traced this expression to an alternative promoter within intron 19. In experimental models, the truncated protein appeared to be phosphorylated, to activate oncogenic signalling pathways, to drive tumour formation, and, tantalisingly, to confer sensitivity to crizotinib. Because the kinase domain remained intact and the inhibitory drugs target that domain, the logic seemed sound: a tumour dependent on ALK ATI signalling might respond to ALK inhibitors even without a fusion. This raised the prospect of a tumour-agnostic biomarker, one that could extend ALK-directed therapy to patients with melanoma, sarcoma and other solid tumours whose cancers lacked canonical ALK rearrangements.

Subsequent laboratory work added layers of intrigue. One study showed that the ALK ATI isoform, in a kinase-activity-dependent manner, induces structural changes in chromatin within the nucleus, suggesting the truncated protein might remodel gene expression programs directly rather than simply relaying signals at the cell surface. Another report found that ALK ATI interacts with the c-Myc oncogene and promotes cancer stem-cell-like properties in sarcoma models, hinting at a role in tumour initiation, metastasis and treatment resistance. More recently, a 2025 study in ovarian high-grade serous carcinoma described a transcriptional variant of ALK that appeared to promote apoptosis, an unexpected and paradoxical finding that complicates any simple story of ALK ATI as a straightforward oncogene. Together, these results painted a picture of a versatile and context-dependent molecule whose effects vary dramatically depending on tumour type and cellular environment.

But the edifice began to crack under the weight of independent replication attempts. As the Spanish review documents in detail, subsequent experiments did not consistently reproduce the original claims of growth-factor-independent transformation or sensitivity to ALK inhibitors. A 2021 study using genomic and experimental evidence concluded that ALK ATI does not predict single-agent sensitivity to ALK inhibitors. In melanoma models expressing the alternative transcript, researchers generally observed low levels of ALK phosphorylation and no selective drug response, undermining the central premise that ALK ATI marks tumours that will benefit from ALK-directed therapy. The discrepancy between the initial excitement and the follow-up data illustrates a familiar pattern in translational cancer research: early findings from a limited set of models can generate hypotheses that broader and more rigorous testing fails to confirm.

The clinical literature on ALK ATI is equally fragmented. Studies across melanoma, sarcoma, ovarian carcinoma and histiocytic neoplasms have been retrospective, have employed heterogeneous assays, and have reported inconsistent prevalence figures and contradictory prognostic associations. In melanoma, where the phenomenon was first described, surveys of primary and metastatic cutaneous tumours confirmed that ALK expression through alternative transcriptional initiation occurs, but its correlation with outcomes has been disputed. In histiocytic neoplasms, a 2026 study reported that ALK ATI drives nuclear ALK expression even in the absence of ALK fusions, adding another layer of complexity to the interpretation of ALK staining in these rare tumours. Meanwhile, isolated case reports, such as a PRKCA-fused blue melanocytoma expressing a truncated ALK isoform, demonstrate that the biology of truncated ALK expression can intersect with other genetic events in unpredictable ways.

Perhaps the most consequential part of the review concerns diagnostics. Standard clinical tests for ALK are simply not designed to detect ALK ATI, and misreading them can lead to dangerous conclusions. ALK immunohistochemistry, which detects the protein regardless of how it is produced, cannot distinguish between expression driven by a fusion, by amplification, by ATI or by aberrant expression in inflammatory conditions such as malakoplakia. Break-apart fluorescence in situ hybridization, which detects physical disruption of the ALK locus, will be negative in ALK ATI because the gene is not rearranged. Confirmation that a tumour expresses ALK ATI requires an RNA-based assay specifically designed to demonstrate transcription initiating from intron 19 and continuing into ALK exons 20 through 29, together with the exclusion of a canonical ALK fusion. Without this molecular rigour, a positive ALK stain in a fusion-negative tumour tells the clinician almost nothing actionable.

The authors’ bottom line is deliberately cautious and carries immediate practical weight for oncologists and pathologists. Current evidence, they conclude, supports ALK ATI as a context-dependent biological phenomenon rather than a validated tumour-agnostic driver or predictive biomarker. In plain terms, finding the transcript in a tumour does not establish that the tumour depends on it, and it certainly does not establish that the patient will benefit from an ALK inhibitor. Accordingly, the review states that ALK-inhibitor treatment should not be selected solely on the basis of ALK ATI outside a clinical trial or a carefully documented individual assessment. This is a direct challenge to any practice of treating ALK-immunopositive, fusion-negative tumours with expensive and toxic targeted drugs on the assumption that the alternative transcript is driving them.

The broader lesson extends beyond a single transcript. Pan-cancer transcriptome analyses have revealed that regulation through alternative promoters is pervasive across the human genome, meaning that many cancer genes likely have truncated or altered isoforms awaiting discovery. Distinguishing passenger transcription from true oncogenic dependence will require the same combination of rigorous functional validation, standardised RNA-based diagnostics and prospective clinical trials that ultimately separated genuine ALK fusions from lookalike findings. For now, ALK ATI stands as a cautionary tale and an open scientific question: a kinase fragment that once promised to widen the reach of precision oncology, and that may yet prove important in specific tumour contexts, but that today remains, in the measured words of the Alicante team, unproven as a basis for treatment decisions.

Subject of Research: The role of the ALK ATI alternative transcript as a potential driver and biomarker in solid tumours

Article Title: ALK ATI in solid tumours: biological evidence, diagnostic challenges, and clinical relevance. a narrative review

Article References: Borregón, M., Algarra, M.-A., & Benítez-Fuentes, J.-D. (2026). ALK ATI in solid tumours: biological evidence, diagnostic challenges, and clinical relevance, a narrative review. Molecular Biology Reports, 53(1), Article 1657. https://doi.org/10.1007/s11033-026-12833-4

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12833-4

Keywords: ALK, ALK ATI, alternative transcription initiation, solid tumours, melanoma, sarcoma, ALK inhibitors, crizotinib, molecular diagnostics, precision oncology, biomarkers, kinase signalling